{ "run": { "id": "cmnr15my3077up6583fskyqhy", "region": "US", "assetId": "cmnr15mxl077qp658e0l1h7iy", "ticker": "ZTS", "snapshotId": "cmnr15mxu077sp6581eevho0x", "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux", "createdAt": "2026-04-09T05:22:13.225Z", "promptTemplate": { "id": "cmnqt07si0005lm3jzpxuu1ux", "name": "Oficial 08.apr.2026", "version": 1 }, "snapshot": { "id": "cmnr15mxu077sp6581eevho0x", "assetId": "cmnr15mxl077qp658e0l1h7iy", "asOf": "2026-04-08T20:00:00.000Z", "snapshot": { "asOf": "2026-04-08T20:00:00.000Z", "quote": { "asOf": "2026-04-08T20:00:00.000Z", "open": 118.78, "price": 119.75, "dayLow": 118.3222, "volume": 2635561, "dayHigh": 119.79, "currency": "USD", "prevClose": 116.8, "week52Low": 113.29, "week52High": 172.23 }, "fundamentals": { "pe": 20.865671641791, "beta": 0.829270955685943, "epsTTM": 6.03, "fcfTTM": 2127000000, "growth": { "epsYoy": 0.1023765996343694, "revenueYoy": 0.02279602420051858 }, "sector": "Pharmaceutical Preparations", "margins": { "net": 0.2823492130558783, "gross": 0.449456005070244, "operating": null }, "website": "http://zoetis.com", "industry": "Pharmaceutical", "pegRatio": 2.0381289978678, "ebitdaTTM": 4097000000, "forwardPe": 18.5029411764706, "marketCap": 69233000000, "totalCash": 2312000000, "totalDebt": 9042000000, "debtEquity": 2.71450015010507, "quickRatio": 1.74586129753915, "revenueTTM": 9467000000, "companyName": "Zoetis Inc.", "priceToBook": 16.7499244250976, "currentRatio": 3.028187919463087, "dividendYield": 0.0160769980279954, "returnOnAssets": 0.1728195513027737, "returnOnEquity": 0.802461723206244, "analystOpinions": null, "businessSummary": "Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total revenue. Contemporaneous with the spinoff in June 2013 S&P Dow Jones Indices announced that Zoetis would replace First Horizon National Corporation in the S&P 500 stock market index.", "enterpriseValue": 62523998260, "analystTargetLow": null, "analystTargetHigh": null, "analystTargetMean": null, "fullTimeEmployees": 13800, "sharesOutstanding": 422127709, "enterpriseToEbitda": 15.26092220161093, "analystTargetMedian": null, "enterpriseToRevenue": 6.604415153691772, "operatingCashflowTTM": 2904000000, "analystRecommendationKey": null } }, "createdAt": "2026-04-09T05:22:13.218Z" }, "results": [ { "id": "cmnr15my6077wp658r4aao18n", "runId": "cmnr15my3077up6583fskyqhy", "modelId": "anthropic", "status": "SUCCESS", "rawOutput": "{\"model\":\"ai-equity-research-v1\",\"as_of\":\"2026-04-08T20:00:00.000Z\",\"ticker\":\"ZTS\",\"currency\":\"USD\",\"current_price\":119.75,\"target_price_6m\":128,\"target_price_12m\":137,\"recommendation\":\"BUY\",\"confidence\":0.62,\"thesis_bullets\":[\"Dominant global animal health franchise with durable competitive moat\",\"Stock trades near 52-week low; forward P/E of 18.5x below historical norms\",\"Revenue growth has decelerated sharply to 2.3% YoY, raising near-term concerns\",\"Strong FCF generation (~$2.1B TTM) supports dividends, buybacks, and deleveraging\",\"Multiple re-rating likely as pet health demand normalizes and pipeline delivers\"],\"key_drivers\":[{\"driver\":\"Pet health spending resilience and companion animal portfolio growth\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Livestock segment cyclical headwinds and slower international demand\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"New product pipeline including monoclonal antibodies for dermatology\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Elevated leverage (D/E 2.71) limits financial flexibility\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Margin expansion potential via operational efficiency and mix shift\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"International revenue (~50%) exposed to FX and trade policy risk\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Share repurchases accretive at depressed valuation levels\",\"impact\":\"LOW\",\"direction\":\"POS\"},{\"driver\":\"Industry consolidation and generic competition in key categories\",\"impact\":\"MED\",\"direction\":\"NEG\"}],\"risks\":[\"Sustained macroeconomic weakness reducing discretionary pet spending\",\"Tariff or trade policy disruption impacting ~50% international revenues\",\"Pipeline disappointments or regulatory delays on key products\",\"Rising interest expense on $9B debt load if rates stay elevated\",\"Competitive pressure from generics and emerging animal health players\",\"Unexpected adverse safety events affecting flagship products\"],\"assumptions\":{\"revenue_cagr_3y\":0.06,\"ebit_margin_target\":0.36,\"wacc\":0.085,\"terminal_multiple\":20},\"scenarios\":{\"bear\":{\"target_price\":105,\"prob\":0.2,\"notes\":\"Prolonged revenue stagnation, multiple compresses to 16x forward earnings.\"},\"base\":{\"target_price\":137,\"prob\":0.55,\"notes\":\"Mid-single-digit growth resumes, multiple normalizes toward 20-21x forward EPS.\"},\"bull\":{\"target_price\":160,\"prob\":0.25,\"notes\":\"Strong pipeline catalysts and pet health rebound drive re-rating toward 24x forward EPS.\"}},\"method_notes\":\"Valuation anchored on forward P/E (18.5x snapshot) with mean-reversion thesis. Base case assumes forward EPS ~$6.50 growing to ~$6.90 in 12M at 20-21x multiple. FCF yield ~3.1% provides downside support. EV/EBITDA at 15.3x is below 5Y average (~22x), suggesting meaningful discount. Revenue CAGR of 6% assumes companion animal normalization and modest livestock recovery. Confidence is medium due to mixed near-term growth signals and macro uncertainty. Not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "ai-equity-research-v1", "risks": [ "Sustained macroeconomic weakness reducing discretionary pet spending", "Tariff or trade policy disruption impacting ~50% international revenues", "Pipeline disappointments or regulatory delays on key products", "Rising interest expense on $9B debt load if rates stay elevated", "Competitive pressure from generics and emerging animal health players", "Unexpected adverse safety events affecting flagship products" ], "ticker": "ZTS", "currency": "USD", "scenarios": { "base": { "prob": 0.55, "notes": "Mid-single-digit growth resumes, multiple normalizes toward 20-21x forward EPS.", "target_price": 137 }, "bear": { "prob": 0.2, "notes": "Prolonged revenue stagnation, multiple compresses to 16x forward earnings.", "target_price": 105 }, "bull": { "prob": 0.25, "notes": "Strong pipeline catalysts and pet health rebound drive re-rating toward 24x forward EPS.", "target_price": 160 } }, "confidence": 0.62, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.06, "terminal_multiple": 20, "ebit_margin_target": 0.36 }, "key_drivers": [ { "driver": "Pet health spending resilience and companion animal portfolio growth", "impact": "HIGH", "direction": "POS" }, { "driver": "Livestock segment cyclical headwinds and slower international demand", "impact": "MED", "direction": "NEG" }, { "driver": "New product pipeline including monoclonal antibodies for dermatology", "impact": "HIGH", "direction": "POS" }, { "driver": "Elevated leverage (D/E 2.71) limits financial flexibility", "impact": "MED", "direction": "NEG" }, { "driver": "Margin expansion potential via operational efficiency and mix shift", "impact": "MED", "direction": "POS" }, { "driver": "International revenue (~50%) exposed to FX and trade policy risk", "impact": "MED", "direction": "NEG" }, { "driver": "Share repurchases accretive at depressed valuation levels", "impact": "LOW", "direction": "POS" }, { "driver": "Industry consolidation and generic competition in key categories", "impact": "MED", "direction": "NEG" } ], "method_notes": "Valuation anchored on forward P/E (18.5x snapshot) with mean-reversion thesis. Base case assumes forward EPS ~$6.50 growing to ~$6.90 in 12M at 20-21x multiple. FCF yield ~3.1% provides downside support. EV/EBITDA at 15.3x is below 5Y average (~22x), suggesting meaningful discount. Revenue CAGR of 6% assumes companion animal normalization and modest livestock recovery. Confidence is medium due to mixed near-term growth signals and macro uncertainty. Not investment advice.", "current_price": 119.75, "recommendation": "BUY", "thesis_bullets": [ "Dominant global animal health franchise with durable competitive moat", "Stock trades near 52-week low; forward P/E of 18.5x below historical norms", "Revenue growth has decelerated sharply to 2.3% YoY, raising near-term concerns", "Strong FCF generation (~$2.1B TTM) supports dividends, buybacks, and deleveraging", "Multiple re-rating likely as pet health demand normalizes and pipeline delivers" ], "target_price_6m": 128, "target_price_12m": 137 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "anthropic", "webSearch": { "enabled": false, "maxToolCalls": 2, "disabledReason": null }, "pauseTurns": 0, "stopReason": "end_turn" }, "sanityIssues": [] }, "latencyMs": 127297, "createdAt": "2026-04-09T05:22:13.225Z", "usage": { "inputTokens": 3675, "outputTokens": 1897, "costUsd": 0.0658 } }, { "id": "cmnr15my6077zp658vcsdyjm6", "runId": "cmnr15my3077up6583fskyqhy", "modelId": "deepseek.reasoner", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"EquityResearchAI\",\n \"as_of\": \"2026-04-08T20:00:00.000Z\",\n \"ticker\": \"ZTS\",\n \"currency\": \"USD\",\n \"current_price\": 119.75,\n \"target_price_6m\": 122,\n \"target_price_12m\": 125,\n \"recommendation\": \"HOLD\",\n \"confidence\": 0.65,\n \"thesis_bullets\": [\n \"Leading animal health company with stable demand.\",\n \"High profitability and strong return on equity.\",\n \"Moderate growth offset by elevated valuation multiples.\",\n \"Significant debt levels increase financial risk.\",\n \"Benefiting from long-term pet healthcare trends.\"\n ],\n \"key_drivers\": [\n { \"driver\": \"New product innovation\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"Expansion in international markets\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"High net margins\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"Elevated debt-to-equity ratio\", \"impact\": \"MED\", \"direction\": \"NEG\" },\n { \"driver\": \"Competitive pressures in animal health\", \"impact\": \"MED\", \"direction\": \"NEG\" },\n { \"driver\": \"Regulatory environment for drug approvals\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"Economic sensitivity of livestock segment\", \"impact\": \"LOW\", \"direction\": \"NEG\" },\n { \"driver\": \"Currency exchange rate volatility\", \"impact\": \"MED\", \"direction\": \"NEG\" }\n ],\n \"risks\": [\n \"Regulatory hurdles for new products.\",\n \"Economic downturn affecting pet spending.\",\n \"Increased competition from generics.\",\n \"Rising interest rates impacting debt.\",\n \"Supply chain disruptions.\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.05,\n \"ebit_margin_target\": 0.25,\n \"wacc\": 0.075,\n \"terminal_multiple\": 15\n },\n \"scenarios\": {\n \"bear\": { \"target_price\": 110, \"prob\": 0.2, \"notes\": \"Growth stalls and margins decline.\" },\n \"base\": { \"target_price\": 125, \"prob\": 0.6, \"notes\": \"Continued execution at current pace.\" },\n \"bull\": { \"target_price\": 140, \"prob\": 0.2, \"notes\": \"Accelerated adoption of new products.\" }\n },\n \"method_notes\": \"Valuation based on DCF with growth and margin assumptions. HOLD due to fair valuation and balanced risk-reward. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "EquityResearchAI", "risks": [ "Regulatory hurdles for new products.", "Economic downturn affecting pet spending.", "Increased competition from generics.", "Rising interest rates impacting debt.", "Supply chain disruptions." ], "ticker": "ZTS", "currency": "USD", "scenarios": { "base": { "prob": 0.6, "notes": "Continued execution at current pace.", "target_price": 125 }, "bear": { "prob": 0.2, "notes": "Growth stalls and margins decline.", "target_price": 110 }, "bull": { "prob": 0.2, "notes": "Accelerated adoption of new products.", "target_price": 140 } }, "confidence": 0.65, "assumptions": { "wacc": 0.075, "revenue_cagr_3y": 0.05, "terminal_multiple": 15, "ebit_margin_target": 0.25 }, "key_drivers": [ { "driver": "New product innovation", "impact": "HIGH", "direction": "POS" }, { "driver": "Expansion in international markets", "impact": "MED", "direction": "POS" }, { "driver": "High net margins", "impact": "HIGH", "direction": "POS" }, { "driver": "Elevated debt-to-equity ratio", "impact": "MED", "direction": "NEG" }, { "driver": "Competitive pressures in animal health", "impact": "MED", "direction": "NEG" }, { "driver": "Regulatory environment for drug approvals", "impact": "HIGH", "direction": "POS" }, { "driver": "Economic sensitivity of livestock segment", "impact": "LOW", "direction": "NEG" }, { "driver": "Currency exchange rate volatility", "impact": "MED", "direction": "NEG" } ], "method_notes": "Valuation based on DCF with growth and margin assumptions. HOLD due to fair valuation and balanced risk-reward. Not investment advice.", "current_price": 119.75, "recommendation": "HOLD", "thesis_bullets": [ "Leading animal health company with stable demand.", "High profitability and strong return on equity.", "Moderate growth offset by elevated valuation multiples.", "Significant debt levels increase financial risk.", "Benefiting from long-term pet healthcare trends." ], "target_price_6m": 122, "target_price_12m": 125 }, "errorsJson": { "attempts": [], "providerMeta": { "endpoint": "https://api.deepseek.com/v1/chat/completions", "provider": "deepseek", "webSearch": { "enabled": false, "supported": false }, "responseFormat": "json_object" }, "sanityIssues": [] }, "latencyMs": 388, "createdAt": "2026-04-09T05:22:13.225Z", "usage": { "inputTokens": 2179, "outputTokens": 3973, "costUsd": 0.002279 } }, { "id": "cmnr15my6077xp658ppidd6qo", "runId": "cmnr15my3077up6583fskyqhy", "modelId": "gemini.3-pro", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"Zoetis_Equity_Model_v1\",\n \"as_of\": \"2026-04-08T20:00:00.000Z\",\n \"ticker\": \"ZTS\",\n \"currency\": \"USD\",\n \"current_price\": 119.75,\n \"target_price_6m\": 130.00,\n \"target_price_12m\": 142.00,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.80,\n \"thesis_bullets\": [\n \"Trading near 52-week lows, ZTS offers a compelling entry point for a high-quality compounder.\",\n \"Forward P/E of 18.5x is historically cheap, pricing in overly pessimistic growth deceleration.\",\n \"Companion animal dermatology and osteoarthritis franchises provide resilient, high-margin recurring revenue streams.\",\n \"Strong FCF generation of $2.1B supports consistent dividend growth and share repurchases.\",\n \"Slowed top-line growth of 2.3% is a headwind, but 10.2% EPS growth shows margin resilience.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Companion animal segment growth\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Osteoarthritis pain meds (Librela/Solensia)\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Macroeconomic pressure on pet spending\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Generic competition in parasiticides\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Livestock segment cyclicality\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Operating margin expansion\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Share repurchase program\",\n \"impact\": \"LOW\",\n \"direction\": \"POS\"\n }\n ],\n \"risks\": [\n \"Increased generic competition in key companion animal parasiticides.\",\n \"Prolonged macroeconomic downturn reducing discretionary veterinary visits and pet spending.\",\n \"Regulatory hurdles or delays in new product pipeline approvals.\",\n \"Adverse weather or disease outbreaks impacting the livestock segment.\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.045,\n \"ebit_margin_target\": 0.38,\n \"wacc\": 0.075,\n \"terminal_multiple\": 22.0\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 96.00,\n \"prob\": 0.20,\n \"notes\": \"Macro pressures persist, revenue growth stalls, and multiple compresses to 16x forward earnings.\"\n },\n \"base\": {\n \"target_price\": 142.00,\n \"prob\": 0.60,\n \"notes\": \"Growth stabilizes at mid-single digits, driving a multiple re-rating to 22x forward earnings.\"\n },\n \"bull\": {\n \"target_price\": 162.00,\n \"prob\": 0.20,\n \"notes\": \"New product launches exceed expectations, restoring historical premium valuation of 25x P/E.\"\n }\n },\n \"method_notes\": \"Target derived using a 22x forward P/E multiple on estimated NTM EPS, supported by a DCF model. The 18.6% upside aligns with a BUY rating. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "Zoetis_Equity_Model_v1", "risks": [ "Increased generic competition in key companion animal parasiticides.", "Prolonged macroeconomic downturn reducing discretionary veterinary visits and pet spending.", "Regulatory hurdles or delays in new product pipeline approvals.", "Adverse weather or disease outbreaks impacting the livestock segment." ], "ticker": "ZTS", "currency": "USD", "scenarios": { "base": { "prob": 0.6, "notes": "Growth stabilizes at mid-single digits, driving a multiple re-rating to 22x forward earnings.", "target_price": 142 }, "bear": { "prob": 0.2, "notes": "Macro pressures persist, revenue growth stalls, and multiple compresses to 16x forward earnings.", "target_price": 96 }, "bull": { "prob": 0.2, "notes": "New product launches exceed expectations, restoring historical premium valuation of 25x P/E.", "target_price": 162 } }, "confidence": 0.8, "assumptions": { "wacc": 0.075, "revenue_cagr_3y": 0.045, "terminal_multiple": 22, "ebit_margin_target": 0.38 }, "key_drivers": [ { "driver": "Companion animal segment growth", "impact": "HIGH", "direction": "POS" }, { "driver": "Osteoarthritis pain meds (Librela/Solensia)", "impact": "HIGH", "direction": "POS" }, { "driver": "Macroeconomic pressure on pet spending", "impact": "MED", "direction": "NEG" }, { "driver": "Generic competition in parasiticides", "impact": "HIGH", "direction": "NEG" }, { "driver": "Livestock segment cyclicality", "impact": "MED", "direction": "NEG" }, { "driver": "Operating margin expansion", "impact": "MED", "direction": "POS" }, { "driver": "Share repurchase program", "impact": "LOW", "direction": "POS" } ], "method_notes": "Target derived using a 22x forward P/E multiple on estimated NTM EPS, supported by a DCF model. The 18.6% upside aligns with a BUY rating. Not investment advice.", "current_price": 119.75, "recommendation": "BUY", "thesis_bullets": [ "Trading near 52-week lows, ZTS offers a compelling entry point for a high-quality compounder.", "Forward P/E of 18.5x is historically cheap, pricing in overly pessimistic growth deceleration.", "Companion animal dermatology and osteoarthritis franchises provide resilient, high-margin recurring revenue streams.", "Strong FCF generation of $2.1B supports consistent dividend growth and share repurchases.", "Slowed top-line growth of 2.3% is a headwind, but 10.2% EPS growth shows margin resilience." ], "target_price_6m": 130, "target_price_12m": 142 }, "errorsJson": { "attempts": [], "providerMeta": { "model": "gemini-3-pro-preview", "provider": "gemini", "webSearch": { "used": false, "allowed": false, "enabled": false, "requested": false, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 25326, "createdAt": "2026-04-09T05:22:13.225Z", "usage": { "inputTokens": 2532, "outputTokens": 908, "costUsd": 0.01596 } }, { "id": "cmnr15my6077vp658n5rqaaca", "runId": "cmnr15my3077up6583fskyqhy", "modelId": "openai.gpt-5.4", "status": "SUCCESS", "rawOutput": "{\"model\":\"AI Model Recommendation v2\",\"as_of\":\"2026-04-08T20:00:00.000Z\",\"ticker\":\"ZTS\",\"currency\":\"USD\",\"current_price\":119.75,\"target_price_6m\":126.0,\"target_price_12m\":132.0,\"recommendation\":\"BUY\",\"confidence\":0.64,\"thesis_bullets\":[\"Category leader in animal health with resilient recurring demand.\",\"EPS growth exceeds revenue growth, showing pricing and mix discipline.\",\"Current valuation is below historical premium for a defensive compounder.\",\"Strong cash generation supports innovation, dividends, and deleveraging.\",\"Low topline growth and leverage cap upside versus past cycles.\"],\"key_drivers\":[{\"driver\":\"Companion animal demand\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"New product uptake\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Price realization\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"International expansion\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Margin discipline\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Livestock market softness\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Generic competition\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Debt burden\",\"impact\":\"LOW\",\"direction\":\"NEG\"}],\"risks\":[\"Slower pet care spending\",\"Regulatory or product setbacks\",\"FX headwinds on international sales\",\"Sustained livestock weakness\",\"Valuation rerates lower despite execution\"],\"assumptions\":{\"revenue_cagr_3y\":5.5,\"ebit_margin_target\":36.0,\"wacc\":8.0,\"terminal_multiple\":22.0},\"scenarios\":{\"bear\":{\"target_price\":102.0,\"prob\":0.25,\"notes\":\"Growth stays muted and multiple compresses on weaker companion animal demand.\"},\"base\":{\"target_price\":132.0,\"prob\":0.5,\"notes\":\"Mid-single-digit sales growth and modest margin expansion support partial rerating.\"},\"bull\":{\"target_price\":150.0,\"prob\":0.25,\"notes\":\"New products accelerate growth and premium multiple returns for a defensive leader.\"}},\"method_notes\":\"12M target uses a blended forward earnings/FCF framework anchored to snapshot fundamentals and labeled assumptions, not sell-side targets. Recommendation matches ~10% 12M upside with moderate uncertainty. not investment advice\"}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "AI Model Recommendation v2", "risks": [ "Slower pet care spending", "Regulatory or product setbacks", "FX headwinds on international sales", "Sustained livestock weakness", "Valuation rerates lower despite execution" ], "ticker": "ZTS", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Mid-single-digit sales growth and modest margin expansion support partial rerating.", "target_price": 132 }, "bear": { "prob": 0.25, "notes": "Growth stays muted and multiple compresses on weaker companion animal demand.", "target_price": 102 }, "bull": { "prob": 0.25, "notes": "New products accelerate growth and premium multiple returns for a defensive leader.", "target_price": 150 } }, "confidence": 0.64, "assumptions": { "wacc": 8, "revenue_cagr_3y": 5.5, "terminal_multiple": 22, "ebit_margin_target": 36 }, "key_drivers": [ { "driver": "Companion animal demand", "impact": "HIGH", "direction": "POS" }, { "driver": "New product uptake", "impact": "HIGH", "direction": "POS" }, { "driver": "Price realization", "impact": "MED", "direction": "POS" }, { "driver": "International expansion", "impact": "MED", "direction": "POS" }, { "driver": "Margin discipline", "impact": "HIGH", "direction": "POS" }, { "driver": "Livestock market softness", "impact": "MED", "direction": "NEG" }, { "driver": "Generic competition", "impact": "MED", "direction": "NEG" }, { "driver": "Debt burden", "impact": "LOW", "direction": "NEG" } ], "method_notes": "12M target uses a blended forward earnings/FCF framework anchored to snapshot fundamentals and labeled assumptions, not sell-side targets. Recommendation matches ~10% 12M upside with moderate uncertainty. not investment advice", "current_price": 119.75, "recommendation": "BUY", "thesis_bullets": [ "Category leader in animal health with resilient recurring demand.", "EPS growth exceeds revenue growth, showing pricing and mix discipline.", "Current valuation is below historical premium for a defensive compounder.", "Strong cash generation supports innovation, dividends, and deleveraging.", "Low topline growth and leverage cap upside versus past cycles." ], "target_price_6m": 126, "target_price_12m": 132 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "openai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "resp_0c07c1f200c199ad0069d75f25d03881959d07b3698008dedc", "reasoningEffort": "medium", "structuredOutputs": { "used": true, "requested": true, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 19424, "createdAt": "2026-04-09T05:22:13.225Z", "usage": { "inputTokens": 2449, "outputTokens": 1006, "costUsd": 0.01837 } }, { "id": "cmnr15my6077yp658qssdin4e", "runId": "cmnr15my3077up6583fskyqhy", "modelId": "xai.grok-4.20-reasoning", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"Integrated DCF Model\",\n \"as_of\": \"2026-04-08T20:00:00.000Z\",\n \"ticker\": \"ZTS\",\n \"currency\": \"USD\",\n \"current_price\": 119.75,\n \"target_price_6m\": 130,\n \"target_price_12m\": 142,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.65,\n \"thesis_bullets\": [\n \"Global leader in animal health with strong brands.\",\n \"High margins and ROE demonstrate business quality.\",\n \"Recent revenue slowdown creates valuation entry point.\",\n \"Robust pipeline supports long-term international growth.\",\n \"Consistent FCF funds innovation and dividends.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Pet humanization trends\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"New product approvals\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Revenue growth deceleration\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Livestock disease management\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Generic competition pressure\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"International market expansion\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"FX volatility on earnings\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"M&A for portfolio growth\",\n \"impact\": \"LOW\",\n \"direction\": \"POS\"\n }\n ],\n \"risks\": [\n \"Generic erosion of pricing power\",\n \"Recession impact on pet spending\",\n \"Regulatory delays for new drugs\",\n \"Foreign exchange rate volatility\",\n \"Supply chain or manufacturing issues\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.06,\n \"ebit_margin_target\": 0.32,\n \"wacc\": 0.085,\n \"terminal_multiple\": 22\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 105,\n \"prob\": 0.25,\n \"notes\": \"Prolonged growth slowdown and margin compression.\"\n },\n \"base\": {\n \"target_price\": 142,\n \"prob\": 0.55,\n \"notes\": \"Steady execution on pipeline with stable demand.\"\n },\n \"bull\": {\n \"target_price\": 175,\n \"prob\": 0.2,\n \"notes\": \"Accelerated growth from new products and share gains.\"\n }\n },\n \"method_notes\": \"DCF using assumed 6% revenue CAGR, 32% EBIT margin, 8.5% WACC and 22x terminal multiple. 12M target implies ~18% upside. not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "Integrated DCF Model", "risks": [ "Generic erosion of pricing power", "Recession impact on pet spending", "Regulatory delays for new drugs", "Foreign exchange rate volatility", "Supply chain or manufacturing issues" ], "ticker": "ZTS", "currency": "USD", "scenarios": { "base": { "prob": 0.55, "notes": "Steady execution on pipeline with stable demand.", "target_price": 142 }, "bear": { "prob": 0.25, "notes": "Prolonged growth slowdown and margin compression.", "target_price": 105 }, "bull": { "prob": 0.2, "notes": "Accelerated growth from new products and share gains.", "target_price": 175 } }, "confidence": 0.65, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.06, "terminal_multiple": 22, "ebit_margin_target": 0.32 }, "key_drivers": [ { "driver": "Pet humanization trends", "impact": "HIGH", "direction": "POS" }, { "driver": "New product approvals", "impact": "HIGH", "direction": "POS" }, { "driver": "Revenue growth deceleration", "impact": "HIGH", "direction": "NEG" }, { "driver": "Livestock disease management", "impact": "MED", "direction": "POS" }, { "driver": "Generic competition pressure", "impact": "MED", "direction": "NEG" }, { "driver": "International market expansion", "impact": "MED", "direction": "POS" }, { "driver": "FX volatility on earnings", "impact": "MED", "direction": "NEG" }, { "driver": "M&A for portfolio growth", "impact": "LOW", "direction": "POS" } ], "method_notes": "DCF using assumed 6% revenue CAGR, 32% EBIT margin, 8.5% WACC and 22x terminal multiple. 12M target implies ~18% upside. not investment advice.", "current_price": 119.75, "recommendation": "BUY", "thesis_bullets": [ "Global leader in animal health with strong brands.", "High margins and ROE demonstrate business quality.", "Recent revenue slowdown creates valuation entry point.", "Robust pipeline supports long-term international growth.", "Consistent FCF funds innovation and dividends." ], "target_price_6m": 130, "target_price_12m": 142 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "xai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "d90194cc-06e4-9307-84fa-2d0dd0cba072", "usedFallbackChatCompletions": false }, "sanityIssues": [] }, "latencyMs": 25028, "createdAt": "2026-04-09T05:22:13.225Z", "usage": { "inputTokens": 2786, "outputTokens": 3973, "costUsd": 0.067953 } } ] } }